Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > ORGANIZATION
ORGANIZATION
- Generic Versions of Combination Drug Exforge to Be Named “Amvalo”: JSGM
June 10, 2014
- Santen President Officially Becomes New OPMA Head
May 29, 2014
- FPMAJ, JPMA Issue Joint Statement Opposing Once-Yearly NHI Price Revision
May 29, 2014
- JPWA Chief Highlights Progress in Single-Product, Single-Price Trading
May 27, 2014
- MTPC, MSD Return to JPMA’s BOD
May 26, 2014
- Yearly NHI Price Revision Not Consistent with Growth Strategy: JPMA Exec
May 23, 2014
- Astellas Chair Nogimori Sworn in as Head of FPMAJ
May 22, 2014
- Dainippon Pres. Tada Elected New Chief of JPMA
May 22, 2014
- Market Share of Generic Drugs Based on New Calculation Method Rose to 44.9% in 3rd Quarter of FY2013: JGA
May 19, 2014
- Quality Control Essential for Preventing Disruptions in Supplies of Generic Drugs; Double-Sourcing Not Enough
May 7, 2014
- Medwatcher Calls for Making Physician Payment Disclosure Obligatory by Law
May 2, 2014
- JPMA Issues New Notification on Promotional Rules Related to Data Presented at Scientific Conferences, Lecture Meetings
May 1, 2014
- Adoption of CDISC Standards Will Be Daunting Task: JPMA Regulatory Affairs Head
April 28, 2014
- JPMA Announces New Guidelines on Support for Clinical Research
April 24, 2014
- Japan Should Stick to Current Mixed Care Scheme: Kenporen Exec Shirakawa
April 22, 2014
- JMA Pres. Yokokura Voices Opposition to Proposed Mixed Care System, Annual Drug Price Revisions
April 21, 2014
- Membership Suspension Appropriate for Novartis Pharma Involvement in SIGN Trial: JPMA
April 21, 2014
- Dainippon’s Takada to Head JPMA Public Affairs Committee
April 18, 2014
- EFPIA Poised to Present Plan for Japan-Version IMI by Year-End
April 16, 2014
- Funding for Investigator-Led Studies Should Be Based on Contracts: EFPIA Japan
April 16, 2014
ページ
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…